Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CTP-543 with Rifampin in Healthy Subjects
NCT04843540Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deuruxolitinib in alopecia areata, sponsored by Concert Pharmaceuticals. Primary endpoints: Area Under the Curve from time zero to last measurable concentration at 16 hours, Area Under the Curve from time zero to infinity at 16 hours and 2 more. Started May 2021; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT04843540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843540.